Simultaneously assess multiple biomarkers from numerous tumor types in a single NGS assay
NGS-based CGP assays provide nucleotide-level resolution of DNA or RNA across multiple genes, enabling identification of numerous types of genomic variants without a priori knowledge of specific mutations. Many of these variants include biomarkers associated with approved and developing therapies across multiple tumor types:
CGP consolidates biomarker detection into a single multiplex assay, eliminating the need for sequential testing. With a single test, you can assess the most prevalent as well as rare biomarkers. By assessing all biomarkers at once, you may increase chances of finding a positive biomarker. This potentially provides faster results, limits the input of precious biopsy samples, and may reduce the need for rebiopsy1-3.
CGP can offer actionable results to help identify more effective therapeutic paths for cancer patients. When tissue biopsies are unavailable, CGP from liquid biopsy may provide helpful information about a tumor's genomic make-up. CGP using tissue and liquid biopsy together may reveal more insights into a tumor's composition.
Modeling studies have shown that by acquiring critical information with higher efficiency, CGP has demonstrated potential cost savings and shorter time to test result 2.
"The key benefit of an NGS approach is that you can combine all of the tests into one single test. It gives you the same answers, quicker."
Professor Andrew Beggs of the University of Birmingham shares his point of view on comprehensive genomic profiling as an approach for assessing biomarkers for therapy selection and clinical trial enrollment.
Single gene assays are limited to a single biomarker. Many times these assays do not cover the entire gene sequence, with the risk of missing important gene alterations.
Targeted panels typically offer hotspot coverage of genes instead of the entire coding sequence. As a result they can miss important alterations.
A comprehensive single assay that assesses a wide range of biomarkers increases the chances of obtaining relevant information vs. targeted panels.
CGP can yield TMB results comparable to whole-exome sequencing at a lower cost.
Because whole-exome sequencing may be cost-prohibitive when developing a personalized medicine approach, there is interest in obtaining accurate TMB assessment with less sequencing.
Comprehensive genomic profiling provides tumor-agnostic testing for hundreds of relevant biomarkers in a single assay, offering significant savings in sample, time, and cost.
Gene content is typically designed to be relevant across multiple tumor types, in contrast to older single-marker or hotspot assays that are often cancer-type specific.
|Pan-Cancer Biomarkers NTRK1 NTRK2 NTRK3 MSI TMB|
The genes shown here are not an exhaustive list.
Learn about critical workflow and bioinformatics considerations when consolidating biomarker testing into a panel that enables CGP from liquid biopsy samples in clinical trials.
In this podcast episode, Dr. Brian Piening of the Providence Cancer Institute explains how NGS is changing the standard of care in oncology.
Experts discuss why they decided to implement in-house CGP, share analytical performance data, and provide details about their end-to-end workflow.
NGS offers the sensitivity researchers need to analyze low levels of circulating tumor DNA (ctDNA) in the bloodstream.
See how NGS can provide insights into immunotherapy response factors and tumor immune evasion mechanisms.
Get a base-by-base view of the unique mutations and genomic alterations present in cancer tissue.
Focus on assessing coding regions, which frequently contain mutations that affect tumor progression.